Small Stocks, Big Money™

VSee Health’s (Nasdaq: VSEE) Q3 2024 revenue surged 131% year-over-year to $3.4 million, driven by its iDoc acquisition and increased demand for engineering and integration services. The company launched initiatives like Aimee, a virtual care platform for uninsured patients, and a telehealth-enabled sea ambulance program using Starlink, while partnering with Ava Robotics for remote ICU care. New agreements with SkywardRx and Seven Corners Correctional Health expanded its reach to enterprise clients and federal prisons. Looking ahead, VSee’s strategic initiatives and robust client base position it for long-term growth in the rapidly evolving telehealth market.

Enlivex Therapeutics (Nasdaq: ENLV) has dosed the first 10 patients in the Phase II stage of its multi-country trial evaluating Allocetra for moderate to severe knee osteoarthritis. Following a successful Phase I safety run-in, the Phase II portion is a randomized, placebo-controlled study designed to assess the safety and efficacy of Allocetra injections on joint pain and function over 12 months. With no safety concerns reported to date, the company aims to address the critical need for treatments that can potentially modify the progression of osteoarthritis, a condition impacting over 300 million people globally.

ASP Isotopes (Nasdaq: ASPI) signed an MOU with the South African Nuclear Energy Corporation (Necsa) to collaborate on the research, development, and production of advanced nuclear fuels, including HALEU for Small Modular Reactors. The proposed facility, to be built at South Africa’s Pelindaba nuclear research center, aims to address global nuclear fuel supply chain challenges and support decarbonization efforts. This partnership is expected to re-establish South Africa as a leader in nuclear engineering while creating significant economic and employment opportunities. ASP’s proprietary enrichment technologies promise efficient, cost-effective fuel production to meet rising global energy demands.

Can-Fite Biopharma (NYSE American: CANF) has begun dosing patients in a Phase IIa trial evaluating Namodenoson for advanced pancreatic adenocarcinoma, following recent Orphan Drug Designation from the FDA. The study, conducted in Israel and the U.S., will assess the safety, clinical activity, and pharmacokinetics of Namodenoson in patients whose cancer has progressed after first-line therapy. Namodenoson, an oral drug targeting the A3 adenosine receptor, has shown promise in other cancers due to its selective action on diseased cells, offering a potential new option for patients with limited treatment alternatives.